{
    "nct_id": "NCT05743842",
    "official_title": "TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning",
    "inclusion_criteria": "* Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent.\n* Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months, and must be non-pregnant with an acceptable contraception in premenopausal women.\n* At least one lesion ≥ 3.0 cm in shortest dimension\n* Negative pregnancy test in premenopausal women\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindications to angiography and selective visceral catheterization\n* Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single injection.\n* Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels)\n* Infiltrative tumors\n* Target vessel sizes outside of TriNav device prescribed diameter range of 1.5 - 3.5 mm",
    "miscellaneous_criteria": ""
}